Navigation Links
Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
Date:6/11/2008

Quark will lead a lecture and present a poster on proprietary siRNA

targeting and delivery approaches

FREMONT, Calif., June 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced it will participate in the Cambridge Healthcare Institute's 9th Annual Beyond Genome Conference on June 8-11, 2008 at The Fairmont Hotel, San Francisco, CA.

Elena Feinstein, M.D., Ph.D., Chief Scientific Officer of Quark Pharmaceuticals will be presenting a lecture, "Temporary Inhibition of p53 of siRNA for Prevention of Acute Renal Failure: From Concept to Clinical Trials," at 1:50 PM (PT) on June 11, 2008.

Dr. Feinstein's lecture will discuss AKIi-5 and Quark's proprietary concept of temporarily inhibiting p53 as a systemic therapy to prevent the development of acute kidney injury (AKI) in response to ischemia-reperfusion stress. Following a successful preclinical program focused on safety, AKIi-5 is currently in Phase I clinical trials and represents the first ever systemic dosing of an siRNA in humans.

Dr. Swetlana Boldin-Adamsky, Project Director of Quark, will give a poster presentation, "Non-invasive Aerosol siRNA Delivery for the Treatment of Lung Tumors." The poster will discuss direct delivery of siRNA to the respiratory system by inhalation, a potential delivery method for various disorders, including lung cancer. Remarkably, the anti-cancer siRNA target utilized in these studies was discovered using Quark's proprietary BiFAR functional gene discovery platform. Targeting this gene for cancer treatment is covered by Quark's intellectual property.

Dr. Feinstein stated, "We are excited to participate in this year's Beyond Genome conference. We have successfully administered the first siRNA drug candidate systemically in humans with the initiation of our AKIi-5 Phase I clinical trial. This acc
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
3. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
4. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
5. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
6. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
7. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
8. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
9. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
10. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Rhythm, a biopharmaceutical company ... deficiencies that result in metabolic disorders, announced today that ... with the U.S. Securities and Exchange Commission (SEC) relating ... its common stock. The number of shares to be ... not yet been determined. Citigroup and Cowen ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
(Date:8/27/2014)... , Aug. 27, 2014 ... report is available in its catalogue: ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... are materials that are readily decomposed by ... from conventional non-degradable packaging in terms of ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7MSC names Mary Beth Loesch President and CEO 2
... ... ... , ... OXFORD, England and LANGHORNE, Pennsylvania, ...
... ... ... , ... ...
... , ... ... ... ...
Cached Biology Technology:EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 2EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 3EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 2Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 3Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 5Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 6Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 7MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 2MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 3MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 4
(Date:8/27/2014)... 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... in the offering consists of 2,000 shares of common ...
(Date:8/27/2014)... of North America,s megafauna mastodons, short-faced bears, giant ... disappeared close to 13,000 years ago at the ... massive extinction has long been debated by scientists who, ... A group of scientists, including UC Santa Barbara,s James ... posited that a comet collision with Earth played a ...
(Date:8/27/2014)... of the human genome was unveiled today in the ... comparison yet of how the genomes of the fruit ... appearing August 28 in in the journal Nature ... species, genomes is "read out," and how their DNA ... add billions of entries to a publicly available archive ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... arrhythmias are killers. They strike without ... about 10 percent of all deaths in the ... molecular mechanism associated with arrhythmias. Their findings, reported ... could lead to novel arrhythmia treatments., "The current ...
... expedition in 1965 to trap moths on Mount Kinabalu in ... groundwork for a study of the impacts of climate change. ... has repeated the survey 42 years later, and found that, ... over the intervening years to cope with changes in climate. ...
... and food research, is coordinating the international TXOTX ... fundamental aim of this project is to collate ... programs from the different regions in the world,s ... cooperation between countries, regional fisheries organisations and other ...
Cached Biology News:Studies point to novel target for treating arrhythmias 2Studies point to novel target for treating arrhythmias 3The global impact of climate change on biodiversity 2TXOTX, coordinated international project to contribute to sustainability of the marine resources 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
... Monoclonal Antibody, Unconjugated Applications: ... ICC: Use at an assay dependent dilution. WB: ... ug/ml, this concentration is determined using a whole ... kDa. Not tested in other applications. Optimal ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Biology Products: